Dr. Silke Wissing
joined CEVEC Pharmaceuticals in September 2011 as Scientist in the Cell Line
Development Department. 2013 she was appointed Director Cell Line Development
and 2016 Director R&D. Before joining CEVEC, she held a position as a group
leader in the Gladstone Institute for Virology and Immunology, San Francisco,
where she performed research in the field of HIV-1 biology, stem cell research
and cell line development. Dr. Silke Wissing holds a PhD in Biochemistry from
the University of Tübingen.